Large Kaiser Permanente Northwest Study: COVID-19 Vax Does Not Adversely Impact Menopausal Bleeding

While TrialSite has reported on studies implicating COVID-19 vaccination and anomalies with the menstrual cycle, a recent large observational study tapping into data at  Kaiser Permanente Northwest found COVID-19 vaccination was not associated with an increase in incident postmenopausal bleeding (PMB) diagnoses. Published in the American Journal of Obstetrics & Gynecology, mass use of COVID-19 mRNA vaccination in the Kaiser Permanente system failed to be associated with an increase in incident postmenopausal bleeding diagnosis. Diagnosis of postmenopausal bleeding in the 60 days following receipt of a COVID-19 vaccination was rare but the study authors did report on some incidence.

Led by the study group known as Vaccine Safety Datalink Menstrual Irregularities Workgroup they sought to understand incident postmenopausal bleeding diagnosis over time before and after COVID-19 vaccine introduction, and to describe cases of new-onset postmenopausal bleeding after COVID-19 vaccination reports the research team represented by Stephanie Irvine, MHS Kaiser Permanente Center for Health Research.